What is the Y-tunnus number of KonePharm Oy?

KonePharm Oy is registered with PRH / YTJ under Y-tunnus 3335044-5.

What is the revenue of KonePharm Oy?

KonePharm Oy reported revenue of EUR 152K in 2025.

Who is the CEO of KonePharm Oy?

Jukka Petteri Lehtinen is Chief Executive Officer of KonePharm Oy, in role since 2023.

Who is the chairman of KonePharm Oy?

Päivi Elina Lehtinen chairs the board of KonePharm Oy, in role since 2023.

Where is KonePharm Oy headquartered?

KonePharm Oy's registered address is Kaukasuontie 240-A.

KonePharm Oy

OYActive

Y-tunnus 3335044-5Kaukasuontie 240-AConstruction of residential and non-residential buildings · NACE 4100Est. 2023— employees

Revenue 2025

EUR 152K

+13% vs 2024

EBITDA margin

2.4%

+8% vs 2024

Equity ratio

40.5%

Financial strength

Net profit 2025

EUR 3K

+8% vs 2024

EBITDA — year on yearEUR millions

Key figuresAnnual report 2025

Revenue	EUR 152K	+13%
EBITDA	EUR 4K	+8%
Net profit	EUR 3K	+8%
Total assets	EUR 14K	+80%
Equity	EUR 6K	+108%
Employees	—	—

Item	2024	2025
Revenue	135	152
Staff expenses	−93	−99
EBITDA	3	4
Depreciation & amort.	−0	−0
EBIT	3	4
Net financials	0	−0
Profit before tax	3	4
Tax	1	1
Net profit	3	3

Item	2024	2025
Total assets	8	14
Equity	3	6
Long-term debt	0	0
Short-term debt	5	8
Total debt	5	8

Name	Role	Member since
Current (2)
JP Jukka Petteri Lehtinen Chief Executive Officer	Chief Executive Officer	2023
ML Merja Liisa Siitonen Deputy Member	Deputy Member	2023

Name	Role	Member since
Current (1)
PE Päivi Elina Lehtinen	Chairperson	2023

Person	Role here	Other companies
Jukka Petteri Lehtinen	Chief Executive Officer	0 companies
Merja Liisa Siitonen	Deputy Member	0 companies
Päivi Elina Lehtinen	Chairperson	0 companies

KonePharm Oy

OYActive

Y-tunnus 3335044-5Kaukasuontie 240-AConstruction of residential and non-residential buildings · NACE 4100Est. 2023— employees

Revenue 2025

EUR 152K

+13% vs 2024

EBITDA margin

2.4%

+8% vs 2024

Equity ratio

40.5%

Financial strength

Net profit 2025

EUR 3K

+8% vs 2024

EBITDA — year on yearEUR millions

Key figuresAnnual report 2025

Revenue	EUR 152K	+13%
EBITDA	EUR 4K	+8%
Net profit	EUR 3K	+8%
Total assets	EUR 14K	+80%
Equity	EUR 6K	+108%
Employees	—	—